SiChem has expanded its portfolio to include GMP manufacturing of pharmaceutical intermediates and active pharmaceutical substances. By establishing a regulatory-compliant production infrastructure, the company strengthens its role as an innovation-driven partner for the development of modern therapies — particularly in personalized medicine, where small quantities of highly specialized, high-purity compounds are required.

As part of an innovation project, a dedicated synthesis laboratory equipped with advanced analytical capabilities has been established. The new infrastructure enables manufacturing and purification under Good Manufacturing Practice (GMP) conditions for both preclinical studies and early clinical development phases. SiChem can now provide the full value chain — from research and development to GMP manufacturing — from a single source.

With this expansion, SiChem positions itself as a competent outsourcing partner for biotech companies, SMEs, research institutions, and the pharmaceutical industry. Innovative drug candidates can be further developed in a regulatory-compliant, flexible, and efficient manner. At the same time, SiChem opens up new market segments in personalized drug development and strengthens its technological competitiveness.

This project is co-financed by the European Union through the European Regional Development Fund (ERDF) and by the Free Hanseatic City of Bremen, represented by the Senator for Economic Affairs, Ports and Transformation. Project administration is carried out by BAB – The Development Bank of Bremen.